These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 9210761)

  • 21. A case of social phobia with obsessive-compulsive symptoms improved by paroxetine in combination with risperidone.
    Yamauchi K; Ohta K; Taniguchi T; Ohmori T
    Gen Hosp Psychiatry; 2004; 26(3):242-3. PubMed ID: 15121355
    [No Abstract]   [Full Text] [Related]  

  • 22. Investigating the efficacy of paroxetine in developmental stuttering.
    Busan P; Battaglini PP; Borelli M; Evaristo P; Monti F; Pelamatti G
    Clin Neuropharmacol; 2009; 32(4):183-8. PubMed ID: 19620850
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Case study: caudate glutamatergic changes with paroxetine therapy for pediatric obsessive-compulsive disorder.
    Moore GJ; MacMaster FP; Stewart C; Rosenberg DR
    J Am Acad Child Adolesc Psychiatry; 1998 Jun; 37(6):663-7. PubMed ID: 9628087
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Eating disorders].
    Kiriike N
    Ryoikibetsu Shokogun Shirizu; 2003; (38):464-8. PubMed ID: 12877027
    [No Abstract]   [Full Text] [Related]  

  • 25. Paroxetine open-label treatment of pediatric outpatients with obsessive-compulsive disorder.
    Rosenberg DR; Stewart CM; Fitzgerald KD; Tawile V; Carroll E
    J Am Acad Child Adolesc Psychiatry; 1999 Sep; 38(9):1180-5. PubMed ID: 10504818
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Paroxetine and its uses in psychiatry.
    Bell C; Nutt D
    Hosp Med; 1999 May; 60(5):353-6. PubMed ID: 10396411
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A review of pharmacologic treatments for obsessive-compulsive disorder.
    Kaplan A; Hollander E
    Psychiatr Serv; 2003 Aug; 54(8):1111-8. PubMed ID: 12883138
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Paroxetine efficacy in stuttering treatment.
    Boldrini M; Rossi M; Placidi GF
    Int J Neuropsychopharmacol; 2003 Sep; 6(3):311-2. PubMed ID: 12975000
    [No Abstract]   [Full Text] [Related]  

  • 29. Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trial.
    Dannon PN; Sasson Y; Hirschmann S; Iancu I; Grunhaus LJ; Zohar J
    Eur Neuropsychopharmacol; 2000 May; 10(3):165-9. PubMed ID: 10793318
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Decrease in thalamic volumes of pediatric patients with obsessive-compulsive disorder who are taking paroxetine.
    Gilbert AR; Moore GJ; Keshavan MS; Paulson LA; Narula V; Mac Master FP; Stewart CM; Rosenberg DR
    Arch Gen Psychiatry; 2000 May; 57(5):449-56. PubMed ID: 10807485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Obsessive-compulsive disorder with non-24-hour sleep-wake syndrome.
    Morinobu S; Yamashita H; Yamawaki S; Tanaka K; Ohkawa M
    J Clin Psychiatry; 2002 Sep; 63(9):838-40. PubMed ID: 12363127
    [No Abstract]   [Full Text] [Related]  

  • 32. Personality changes in adult subjects with major depressive disorder or obsessive-compulsive disorder treated with paroxetine.
    Brody AL; Saxena S; Fairbanks LA; Alborzian S; Demaree HA; Maidment KM; Baxter LR
    J Clin Psychiatry; 2000 May; 61(5):349-55. PubMed ID: 10847309
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Olanzapine-sertraline combination in schizophrenia with obsessive-compulsive disorder.
    Poyurovsky M; Kurs R; Weizman A
    J Clin Psychiatry; 2003 May; 64(5):611. PubMed ID: 12755669
    [No Abstract]   [Full Text] [Related]  

  • 34. Effectiveness of paroxetine in the treatment of obsessive-compulsive disorders.
    Kamijima K; Aoki M
    Expert Rev Neurother; 2006 Jul; 6(7):945-56. PubMed ID: 16831110
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
    Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
    Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sertraline and obsessive compulsive disorder: new indication. Limited assessment.
    Prescrire Int; 2000 Aug; 9(48):112-3. PubMed ID: 11067720
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treatment of comorbid obsessive-compulsive and depressive disorders in children age].
    Goriunov AV; Lobacheva MV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(11 Pt 2):48-52. PubMed ID: 23257756
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential brain metabolic predictors of response to paroxetine in obsessive-compulsive disorder versus major depression.
    Saxena S; Brody AL; Ho ML; Zohrabi N; Maidment KM; Baxter LR
    Am J Psychiatry; 2003 Mar; 160(3):522-32. PubMed ID: 12611834
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fluvoxamine: new indication. No progress in obsessive-compulsive disorder.
    Prescrire Int; 2004 Oct; 13(73):163-5. PubMed ID: 15499694
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma oxytocin changes and anti-obsessive response during serotonin reuptake inhibitor treatment: a placebo controlled study.
    Humble MB; Uvnäs-Moberg K; Engström I; Bejerot S
    BMC Psychiatry; 2013 Dec; 13():344. PubMed ID: 24359174
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.